Scholarlink

Background <p>The impact of glycemic variability (GV) on muscle mass in type 2 diabetes mellitus (T2DM) remains unclear under the updated Asian Working Group for Sarcopenia (AWGS) 2025 criteria. We investigated the association between continuous glucose monitoring (CGM)-derived GV and low skeletal muscle mass (LSMM).</p> Methods <p>This cross-sectional study included 614 hospitalized T2DM patients aged ≥ 50 years. GV metrics (SD, MODD, LAGE, and CV) were derived from 7-day CGM data. LSMM was identified using bioelectrical impedance analysis based on age-specific AWGS 2025 thresholds. Multivariate logistic regression, restricted cubic splines (RCS), subgroup, and mediation analyses were performed.</p> Results <p>Patients with LSMM exhibited significantly higher GV. In fully adjusted models, higher SD (OR = 1.36), MODD (OR = 1.38), and LAGE (OR = 1.08) were independently associated with increased LSMM risk (all <i>p</i> &lt; 0.05). RCS analysis revealed a linear dose-response relationship between GV and LSMM. Subgroup analyses demonstrated consistent associations across BMI, eGFR, sex, age and HbA1c categories (all <i>p</i> for interaction &gt; 0.05). Mediation analysis indicated that insulin sensitivity-related indices (HOMA2-IR) partially mediated the GV-LSMM relationship.</p> Conclusions <p>Elevated GV is independently associated with LSMM in middle-aged and older adults with T2DM, showing a linear dose-response pattern consistent across diverse clinical profiles. Strategies targeting glucose fluctuations may be crucial for preserving muscle mass in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Continuous glucose monitoring-derived glycemic variability and low skeletal muscle mass in middle-aged and older adults with type 2 diabetes mellitus: an analysis using AWGS 2025 criteria

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月4日

查看全文
  • Yanling Yang,
  • Hongrong Deng,
  • Beisi Lin,
  • Yintong Huang,
  • Jinhua Yan,
  • Xubin Yang,
  • Cailian Cheng,
  • Wen Xu

摘要

Background

The impact of glycemic variability (GV) on muscle mass in type 2 diabetes mellitus (T2DM) remains unclear under the updated Asian Working Group for Sarcopenia (AWGS) 2025 criteria. We investigated the association between continuous glucose monitoring (CGM)-derived GV and low skeletal muscle mass (LSMM).

Methods

This cross-sectional study included 614 hospitalized T2DM patients aged ≥ 50 years. GV metrics (SD, MODD, LAGE, and CV) were derived from 7-day CGM data. LSMM was identified using bioelectrical impedance analysis based on age-specific AWGS 2025 thresholds. Multivariate logistic regression, restricted cubic splines (RCS), subgroup, and mediation analyses were performed.

Results

Patients with LSMM exhibited significantly higher GV. In fully adjusted models, higher SD (OR = 1.36), MODD (OR = 1.38), and LAGE (OR = 1.08) were independently associated with increased LSMM risk (all p < 0.05). RCS analysis revealed a linear dose-response relationship between GV and LSMM. Subgroup analyses demonstrated consistent associations across BMI, eGFR, sex, age and HbA1c categories (all p for interaction > 0.05). Mediation analysis indicated that insulin sensitivity-related indices (HOMA2-IR) partially mediated the GV-LSMM relationship.

Conclusions

Elevated GV is independently associated with LSMM in middle-aged and older adults with T2DM, showing a linear dose-response pattern consistent across diverse clinical profiles. Strategies targeting glucose fluctuations may be crucial for preserving muscle mass in this population.